

PROBIOTICS RESOURCE CENTER

Theater Schedule

Speakers Bio & Abstract

DAY 2

Thursday November 3, 2022

10:30 – 11:10

John Hale, PhD
Chief Technology Officer



Bio

John was drawn to the field of Microbiology, interested in how bacteria cause significant diseases and what options there are to counter them. This led him to carry out graduate studies studying the potential of bacteria to be probiotics at the Department of Microbiology and Immunology, University of Otago, New Zealand. Specifically, he characterised different bacterial produced anti-competitor molecules known as bacteriocin's. Following this, he carried out post-doctoral research in the lab of Professor Bob Hancock at the University of British Columbia (Vancouver, Canada) characterising the mode of action of bacteriocins; and then as a Research Fellow at Monash University's School of Pharmacy (Melbourne, Australia) investigating how pathogens respond and try to resist bacteriocins. He joined Blis Technologies in 2011 and now as Chief Technology Officer he leads the Scientific Services Team and oversees R&D, Clinical, Regulatory and IP programs looking at identifying, characterising, and developing probiotic bacteria for health benefits. He also holds an adjunct Senior Lecturer position with the Department of Microbiology and Immunology, University of Otago, New Zealand.

Company

Blis Technologies (www.blis.co.nz) is a New Zealand based developer and manufacturer of innovative probiotic solutions. Founded on the research of Professor John Tagg (University of Otago, New Zealand) the company was formed in 2000 to develop new bacterial species as probiotics for human health applications. To date, the company has developed three strains with applications for ENT/immune health (BLIS K12), dental health (BLIS M18) and (BLIS Q24) for topical skin applications.



Use of oral probiotics to support upper respiratory health

Abstract

The respiratory tract provides a variety of habitats for the development of complex microbial communities. Each of these habitats is potentially vulnerable to microbial disequilibria resulting in a variety of diseases that can occur at various stages of life. This talk will introduce and update the audience on the exciting developments on *Streptococcus salivarius* as a probiotic for human health applications.

Key Elements

- What is *Streptococcus salivarius* and why is it considered as a probiotic
- Why consider the mouth and throat and thus the respiratory tract for delivery of oral probiotics
- Presentation of key clinical trials demonstrating the value of orally targeted probiotics